2023 World Conference on Lung Cancer (Posters)-EP17.03. Pharmacoeconomic Analysis of Brigatinib Versus Alectinib in Chinese Patients with ALK-Positive Non-Small Cell Lung Cancer

EP17.03. Pharmacoeconomic Analysis of Brigatinib Versus Alectinib in Chinese Patients with ALK-Positive Non-Small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This study examined the pharmacoeconomic analysis of brigatinib versus alectinib in Chinese patients with ALK-positive non-small cell lung cancer (NSCLC). Alectinib and brigatinib are both ALK tyrosine kinase inhibitors used to treat advanced NSCLC in China. The researchers used a partition survival model to simulate health outcomes and costs over a 30-year period. The clinical efficacy and safety data were based on the ALTA-1L trial for brigatinib and the ALEX trial for alectinib. Since there were no head-to-head trials comparing the two drugs, a matching-adjusted indirect comparison (MAIC) was performed to obtain comparative efficacy. The study conducted a cost-minimization analysis and found that brigatinib was cost-saving compared to alectinib. Additionally, a cost-effectiveness analysis showed that brigatinib gained incremental quality-adjusted life-years (QALYs) and was less costly than alectinib. Sensitivity analyses revealed that drug costs were the most influential factor. Thus, the authors concluded that brigatinib is cost-saving and economically dominant compared to alectinib for the treatment of ALK-positive advanced NSCLC in China.

Asset Subtitle

Congling Gu

Meta Tag

Speaker Congling Gu

Topic Global Health, Health Services & Health Economics: Health Economics

Keywords

pharmacoeconomic analysis

brigatinib

alectinib

ALK-positive NSCLC

partition survival model

cost-minimization analysis

cost-saving

QALYs

sensitivity analyses

China